Vasectomy reversal: no impact on prostate cancer risk

  • Randall S & et al.
  • J Urol
  • 7 mars 2018

  • de Deepa Koli
  • Résumé d’articles
L'accès à l'intégralité du contenu de ce site est reservé uniquement aux professionnels de santé disposant d'un compte. L'accès à l'intégralité du contenu de ce site est reservé uniquement aux professionnels de santé disposant d'un compte.

Takeaway

  • A meta-analysis suggests that vasectomy reversal does not provide protection against prostate cancer; no causal relationship between vasectomy and prostate cancer could be established.

Why this matters

  • Studies reporting small or no risk for prostate cancer in vasectomized men are criticized for detection bias.
  • If vasectomy increases the risk for prostate cancer, then the risk would be lower in men who subsequently undergo vasectomy reversal.

Study design

  • This meta-analysis compared data of 9754 men with vasectomy reversal and 684,660 men who underwent vasectomy but no reversal across 5 regions.
  • Funding: None.

Key results

  • Median follow-up in vasectomy-only cohort was 7-21 years and in vasectomy-reversal cohort was 7-19 years.
  • Median time to vasectomy reversal was 4-7 years.
  • The combined risk for prostate cancer was similar between both groups (HR, 0.92; 95% CI, 0.70-1.21; no heterogeneity).

Limitations

  • Details of screening, levels of healthcare provider engagement were unknown.
  • Not all vasectomies and vasectomy-reversal procedures were included.